Intention-to-treat population (n=89). Data for analysis by hormonal control exclude one patient with missing post-baseline IGF-1 assessment (this patient had intrasphenoidal and cavernous, but not suprasellar, extension). As per the primary endpoint of the core study, hormonal control was defined as achievement of GH ≤2.5 μg/L with normalized IGF-1. Tumor response was defined as tumor volume reduction ≥20%.

GH, growth hormone; IGF-1, insulin-like growth factor 1; LVA, last visit available; MRI, magnetic resonance imaging.